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Background 
Micropapillary (MP) predominant adenocarcinoma is one of adenocarcinoma phenotypes 
and known as highly malignant potential type. Although the incidence of MP predominant 
adenocarcinoma is low (0.85–16.2%), adenocarcinoma containing MP pattern as its 
non-dominant component (including > 1% MP component) is commonly detected 
(10.7–65.8%) and is also associated with poor prognosis. MP components often coexist with 
papillary (PaP) components or accompany PaP predominant adenocarcinoma. These 2 
subtypes are distinguished based on the morphology. The clinicopathological or genetic 
characteristics of patients with MP component have been evaluated. The specific genetic 
variants of the MP component have not been reported. It also remains unknown whether 
MP component and PaP component vary genetically; if they vary, how the difference is 
related to the malignant potential on patients with MP component. We comprehensively 
compared mRNA expression between the MP and PaP components in the same patient and 
explored to identify the genetic traits responsible for the poorer prognosis in patients with 
the MP component. 
Materials and methods 
Primary lung adenocarcinoma patients with > 20% MP component and PaP component were 
selected for mRNA expression analysis. MP and PaP components were separately captured 
from formalin-fixed paraffin embedded tissue by laser microdissection and mRNA was 
extracted from 10 patients. RNA of adequate quality (> 100 ng and ≥ 50% DV200 after 
purification) could be extracted from both the MP and PaP components in three patients. 
Comprehensive mRNA expressions of somatic variants were compared between MP and PaP 
components of each patient using next-generation sequencing (NGS). NGS was performed 
with a HiSeq 2500 (Illumina, San Diego, CA, USA). Sequence reads were processed and 
mapped to a human genome reference sequence (hg19) with TopHat v. 2.0.14. Mutations 
were detected with GATK v. 3.6 according to GATK Best Practices (GATK. 
https://software.broadinstitute.org/gatk/). Somatic variants were detected with varscan v. 
2.4.2 at the default setting. Fisher’s exact test was used to determine the significance level 
of allele frequency. Detected mutations were annotated with snpEff v. 4.2 
(http://snpeff.sourceforge.net/). Somatic variants were considered cancer-related if they were 
detected in COSMIC (https://cancer.sanger.ac.uk/cosmic). The protein expression of 
NGS-detected genetic variant was validated by immunohistochemistry (IHC); The 
immunoreactivity levels (staining intensity and the proportion of positive cells) of the MP 
and PaP components were compared between MP and PaP component. Furthermore, 
prognostic impact of NGS-detected variant was evaluated in 288 invasive (excluding 
minimally invasive adenocarcinoma) pN0M0 adenocarcinoma patients using overall 
survival (OS) and recurrence-free survival (RFS). 
Results 
The numbers of genetic variants detected in the MP and PaP components of 3 patients by 
NGS were 93077-179002 and 83427-186031, respectively. Among them, 9-23 pathogenic or 
cancer-related variants were detected in each patient. Cancer-related variants were more 
frequently detected in the MP component of each patient and one variant in EGFR (L858R) 
was expressed at significantly higher levels in two patients (allele frequency = 0.485 vs 
0.155 and 1.000 vs 0.526, respectively P < 0.001 in both). IHC was performed to validate the 
NGS results in 27 MP-positive patients harboring L858R. All 27 patients had the PaP 
component and 17 cases presented with heterogenous intratumor immunoreactivity. IHC 
score for L858R protein was significantly higher in MP components (P < 0.001). Of the 288 
invasive pN0M0 adenocarcinoma patients, the MP-positive patients were more often 
included among the PaP-predominant patients. MP-positive patients showed significantly 
higher frequencies of pleural invasion, lymphatic and vascular invasion, L858R mutation, 
and recurrence than MP-negative patients. The five-year RFS were 87.6% and 75.6% in the 
MP-negative and MP-positive patients, respectively. The five-year RFS for the MP-/L858R-, 
MP-/ L858R+, MP+/ L858R-, and MP+ /L858R+ cases were 89.4%, 84.2%, 84.6%, and 46.9%, 
respectively. MP-positive patients showed significantly worse RFS than MP-negative 
patients (MP- vs. MP+: hazard ratio (HR) = 2.074, 95% confidence interval (CI) = 
1.116–4.616, P = 0.024). There was no significant difference between the MP-negative 
patients without the L858R mutation and those harboring L858R in terms of RFS 
(MP-/L858R- vs. MP-/L858R+: HR = 1.061, 95% CI = 0.380–2.968, P = 0.909). In contrast, 
MP+/L858R+ patients presented with significantly worse RFS than MP+/L858R- patients 
(MP+/L858R- vs. MP+/L858R+: HR = 3.004, 95% CI = 1.306–9.132, P = 0.012). Multivariate 
analysis in MP-positive patients revealed positive L858R status was associated with poorer 
RFS (HR = 2.976, 95% CI = 1.190–7.442; P = 0.020). The five-year OS were 93.1% and 85.4% 
for the MP-negative and MP-positive patients, respectively. The five-year OS for the 
MP-/L858R-, MP-/L858R+, MP+/L858R-, and MP+/L858R+ were 92.8%, 95.1%, 87.0%, and 
81.8%, respectively. There were no significant differences in OS among any of the variants. 
Conclusions 
Micropapillary component of lung adenocarcinoma was genetically characterized by EGFR 
L858R, which is also related to malignant potential. EGFR L858R is more frequently 
harbored in MP-positive adenocarcinoma patients than in MP-negative adenocarcinoma 
patients. Intense expression of L858R was suggested in MP component and MP-positive 
patients harboring L858R are at comparatively higher risk of recurrence in pN0M0 lung 
adenocarcinoma. 
